Gabather AB (publ) (STO:GABA)

Market Cap	22.83M +124.8%
Revenue (ttm)	n/a
Net Income	-4.65M
EPS	-0.02
Shares Out	610.49M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,997,212
Open	0.0400
Previous Close	0.0400
Day's Range	0.0374 - 0.0410
52-Week Range	0.0230 - 0.1300
Beta	-0.71
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 5, 2026

About Gabather AB

Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer’s disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer’s disease, schizophrenia, and major depressive disorders. The company was incorporated in 2014 and is based in Södertälje, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Employees: 3
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GABA